Skip to content

Aramis Biosciences is a clinical-stage immuno‑ophthalmology biopharmaceutical company committed to the development of disease‑modifying therapy for ocular surface disease

World‑Renowned Experts

Validating Partnerships

Accomplished Leadership

Aramis Biosciences was founded in 2018 following more than a decade of research at The Schepens Eye Research Institute of Mass Eye and Ear and Department of Ophthalmology at Harvard Medical School, where the role of a certain subset of pro-inflammatory T helper cells were found to be central to the immunopathogenesis of dry eye disease.

Since then, Aramis Biosciences has assembled a team of accomplished pharmaceutical executives and world-renowned experts in the fields of ophthalmology and immunology, all committed to Aramis Biosciences’ mission to revolutionize the standard of care in ocular surface disease. Aramis Biosciences is further supported by its strategic partners, institutional investors and academic collaborators.

Board of Directors

Sunil Chauhan, DVM, PhD

Scientific Co-Founder
Mass Eye and Ear, Harvard Medical School

Tsuyoshi (Josh) Chiwata, MS

Santen Ventures

Michael Goldstein, MD, MBA

Aurion Biotech

Nader Motamedy, MBA

Safar Partners

David S. Tierney, MD

President and Chief Executive Officer

Scientific Advisory Board

Reza Dana, MD, MPH, MSc

Scientific Co-Founder
Mass Eye and Ear, Harvard Medical School

Gary Foulks, MD

University of Louisville School of Medicine

Michael Goldstein, MD, MBA

President and Chief Medical Officer at Aurion Biotech
Tufts University School of Medicine
New England Eye Center

Reza Haque, MD, PhD

SVP and Global Head of Ophthalmic Innovation Center, Global R&D at Santen

Ed Holland, MD

Cincinnati Eye Institute
University of Cincinnati


Aramis Biosciences was founded to revolutionize the standard of care in ocular immunology, beginning with Dry Eye Disease.

See our pipeline